Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Novartis : Patent Issued for Formulation Comprising Benzothiazolone Compound (USPTO 9623012)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2017 | 08:37pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- NOVARTIS AG (Basel, CH) has been issued patent number 9623012, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors (see also Pharmaceutical Companies).

The patent's inventors are Achour, Miloud (Basel, CH); Fairhurst, Robin Alec (Basel, CH); Grandeury, Arnaud (Basel, CH); Hatakeyama, Shinji (Basel, CH); Koziczak-Holbro, Magdalena (Basel, CH); Tufilli, Nicola (Basel, CH); Ullrich, Thomas (Basel, CH).

This patent was filed on February 26, 2014 and was published online on April 18, 2017.

From the background information supplied by the inventors, news correspondents obtained the following quote: "Benzothiazolone compounds which are beta-2-adrenoceptor agonists are described in WO2004/16601 and WO2006/056471. WO2005/110990 also describes benzo-condensed heterocycles as beta-2 agonists.

"While beta-2 agonists have long been known for their bronchodilating properties, they are also known for their capability to produce skeletal muscle hypertrophy.

"Numerous studies have focused on therapeutic applications of the anabolic properties of beta-2 agonists for ameliorating muscle wasting and improving muscle function. However, this class of compounds has also been associated with undesirable side-effects, including increased risk of adverse cardiovascular-related events. Thus, the use of beta-2 agonists in muscle wasting diseases has hitherto been limited by cardiac hypertrophy and potentially deleterious effects on cardiovascular function.

"There is a need to provide new beta-2 agonists that are good drug candidates. In particular, a new beta-2 agonist should bind potently to the beta-2 adrenoceptor whilst showing little affinity for other receptors, such as e.g. the beta-1 adrenoceptor, the alpha-1A adrenoceptor, or the 5HT.sub.2C receptor, and show functional activity as an agonist. It should be metabolically stable and possess favourable pharmacokinetic properties. It should be non-toxic and demonstrate few side-effects, in particular fewer cardiac side-effects than known marketed beta-2 agonists, such as e.g. formoterol. Furthermore, the ideal drug candidate will exist in a physical form that is stable, non-hygroscopic and easily formulated."

Supplementing the background information on this patent, NewsRx reporters also obtained the inventors' summary information for this patent: "There is therefore a need to provide a compound having at least some of the properties described above wherein the compound is in a physical form which may improve efficiency, bioavailability, stability and/or acceptance by the patient.

"These objectives are aimed to be achieved by providing a composition as described herein, by providing the composition for use in diseases, particular for the treatment of muscular dystrophy, disuse-related atrophy, cachexia or sarcopenia, as described herein and by providing a process to produce the composition as described herein.

"Various embodiments of the invention are described herein.

"Within certain aspects, provided herein is a pharmaceutical composition in solid oral dosage form comprising 0.01 to 15% (w/w) of ®-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-- hydroxybenzo[d]thiazol-2(3H)-one and one or more pharmaceutically acceptable excipients, wherein ®-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-- hydroxybenzo[d]thiazol-2(3H)-one is in acetate salt form.

"In another embodiment, the invention provides a method for the manufacture of said pharmaceutical composition.

"In another embodiment, the invention provides a method of treatment or prevention of muscular dystrophy, disuse-related atrophy, cachexia or sarcopenia comprising administering said pharmaceutical composition."

For the URL and additional information on this patent, see: Achour, Miloud; Fairhurst, Robin Alec; Grandeury, Arnaud; Hatakeyama, Shinji; Koziczak-Holbro, Magdalena; Tufilli, Nicola; Ullrich, Thomas. Formulation Comprising Benzothiazolone Compound. U.S. Patent Number 9623012, filed February 26, 2014, and published online on April 18, 2017. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9623012.PN.&OS=PN/9623012RS=PN/9623012

Keywords for this news article include: Pharmaceutical Companies, Cachexia, Cardiology, Sarcopenia, NOVARTIS AG, Cardiovascular, Muscular Atrophy, Risk and Prevention, Muscular Dystrophies, Neurologic Manifestations, Atrophic Muscular Disorders, Neuromuscular Manifestations, Neuromuscular Diseases and Conditions, Nervous System Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
08:37p NOVARTIS : Patent Issued for Formulation Comprising Benzothiazolone Compound (US..
06:48p NOVARTIS : Allergan Expands Leading Research & Development NASH Program with Nov..
05:34p NOVARTIS : CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designati..
05:11p NOVARTIS : Patent Application Titled "Use of Serelaxin to Reduce Gdf-15" Publish..
11:31a NOVARTIS : to globally co-commercialise Amgen's migraine drug
10:23a NOVARTIS : and Amgen expand global collaboration to commercialise AMG 334
04/26 NOVARTIS : Justices hear dispute over lower-cost biotech drugs sales
04/26 MEREO BIOPHARMA : Issues Shares To Novartis For Loan Note Conversion (ALLISS)
04/26 NOVARTIS : $32,030 Federal Contract Awarded to Alcon Laboratories
04/26 NOVARTIS : Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive gl..
More news
Sector news : Pharmaceuticals - NEC
09:02pDJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
10:10aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
09:41aDJASTRAZENECA : Correction to AstraZeneca Profit Drops on Decline in Blockbuster-D..
09:26aDJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion -- Update
08:48aDJGLAXOSMITHKLINE : New Glaxo CEO Seeks Tighter Drug Focus -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:08p Amgen's Q1 Shows Challenges And Growth Opportunities Aplenty
01:17p G1 Therapeutics Seeks $115 Million IPO
09:54a 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 28, 2017
04/26 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2017 Update
04/26 Novartis Pushes Pipeline But Keeps An Eye On Alcon
Advertisement
Financials ($)
Sales 2017 48 401 M
EBIT 2017 12 341 M
Net income 2017 7 465 M
Debt 2017 14 141 M
Yield 2017 3,69%
P/E ratio 2017 22,42
P/E ratio 2018 19,74
EV / Sales 2017 4,45x
EV / Sales 2018 4,25x
Capitalization 201 384 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 79,7 $
Spread / Average Target 3,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.77%201 384
JOHNSON & JOHNSON7.20%334 822
ROCHE HOLDING LTD.10.83%223 653
PFIZER INC.3.94%201 581
MERCK & CO., INC.6.51%171 894
SANOFI11.38%120 619
More Results